United States v. Jarjoura

District Court, W.D. Oklahoma·Decided July 11, 2025·No. 5:23-cv-00680·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF OKLAHOMA

UNITED STATES OF AMERICA, ) ) Plaintiff, ) ) v. ) Case No. CIV-23-680-D ) ELI JARJOURA, D.D.S., ) ) Defendant. )

ORDER Before the Court is Defendant’s Daubert Motion to Exclude Certain Opinions of Bruce Horn [Doc. No. 33]—Plaintiff’s expert witness. Plaintiff filed a Response [Doc. No. 41]. Defendant did not reply. The matter is fully briefed and ripe for consideration. BACKGROUND This case arises out of Plaintiff’s allegations that Defendant dispensed Schedule IV controlled substances without a “legitimate medical purpose . . . in the usual course of his professional practice” in violation of 21 U.S.C. §§ 829, 842(a)(1). Compl. at 1. Plaintiff seeks statutory penalties under 21 U.S.C. § 842(a)(1) and 842(c)(1)(A). Id. at 4. Dr. Horn is Plaintiff’s expert witness on dentistry and sedation practice. See Report [Doc. No. 37 at p. 1]. Dr. Horn’s report, submitted pursuant to Rule 26, opines on “whether prescriptions written and issued by [Defendant] . . . were (i) issued for a legitimate medical purpose; and/or (ii) issued within the ordinary course of professional practice.” Id. To arrive at his opinions, Dr. Horn first reviewed Defendant’s patient records and then compared the practices described therein with commonly accepted practices in the dental field, as well as Dr. Horn’s own experience. Id. at 1-2. Dr. Horn concluded that Defendant’s prescription practices regarding certain sedation drugs had no “legitimate

medical purpose and were outside the course of usual professional practice.” Id. at 1. Specifically, Dr. Horn makes three related contentions. First, Dr. Horn notes that Defendant prescribed abnormally high quantities of the benzodiazepines Triazolam and Alprazolam despite no “reliable, accepted publication supporting the combined use of these [two] sedatives in sedation dentistry.”1 Id. at 9-12. Second, Dr. Horn contends that

Defendant’s recordkeeping was deficient. Id. at 12-13. In his words, “sedation dental practice . . . [should be based] on the individual characteristics of each patient,” and patient records should contain these details to ensure “safe dosing[,]” but Defendant’s records lacked the requisite detail. Id. Third, Dr. Horn asserts that Defendant could not have effectively monitored his patients given the amount of sedation medication administered.

Id. at 13-14. Such levels of sedation medication, Dr. Horn argues, would have placed Defendant’s patients in physical danger. Id. In the instant motion, Defendant argues that Dr. Horn’s opinion should be excluded pursuant to Fed. R. Evid. 702. Defendant asserts Dr. Horn lacks the qualifications necessary to comment on prescription drug safety and drug interactions because he is

trained as a dentist and not as a pharmacist.

1 Dr. Horn notes that “[i]t is not the usual professional practice to prescribe excessive dosages and large quantities of Benzodiazepines for a single dental encounter without a legitimate medical purpose.” Id. at 9. Defendant further argues that certain portions of Dr. Horn’s report are either irrelevant or prejudicial. Def. Mot. to Excl. at 1-2; 5-7. Defendant cites to portions of the report in which Dr. Horn comments on the following topics: (1) the presence of expired

sedative antagonists in Defendant’s office stock; (2) Defendant’s practice of intravenously administering the benzodiazepine Midazolam; (3) the accuracy of Defendant’s medical recordkeeping; (4) appropriate dosing of prescriptions kept in Defendant’s office stock; (5) the application of the Oklahoma Board of Dentistry statutes and regulations to Defendant’s practice; and (6) the proper monitoring of patients during conscious sedation.

STANDARD Federal Rule of Evidence 702 imposes upon the Court an important gatekeeping function in determining the admissibility of expert opinions: A witness who is qualified as an expert by knowledge, skill, experience, training, or education may testify in the form of an opinion or otherwise if the proponent demonstrates to the court that it is more likely than not that: (a) the expert’s scientific, technical, or other specialized knowledge will help the trier of fact to understand the evidence or to determine a fact in issue; (b) the testimony is based on sufficient facts or data; (c) the testimony is the product of reliable principles and methods; and (d) the expert has reliably applied the principles and methods to the facts of the case. Fed. R. Evid. 702. The proponent of expert testimony bears the burden of establishing its admissibility. See United States v. Nacchio, 555 F.3d 1234, 1241 (10th Cir. 2009). In considering whether an expert’s opinion is admissible, the Court performs a two-step analysis. 103 Investors I, L.P. v. Square D Co., 470 F.3d 985, 990 (10th Cir. 2006). First, the Court determines whether the expert is qualified by knowledge, skill, experience, training, or education to render the opinion offered. Id. Second, if the expert is qualified, the Court must decide

whether the expert’s opinion is reliable under the principles set forth in Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993) and Kumho Tire Co. v. Carmichael, 526 U.S. 137 (1999). Id. Courts have broad discretion in determining the admissibility of expert testimony. Taylor v. Cooper Tire & Rubber Co., 130 F.3d 1395, 1397 (10th Cir. 1997). They decide

“how to assess an expert’s reliability, including what procedures to utilize in making that assessment, as well as in making the ultimate determination of reliability.” Dodge v. Cotter Corp., 328 F.3d 1212, 1223 (10th Cir. 2003) (citing Kumho Tire, 526 U.S. at 152; United States v. Velarde, 214 F.3d 1204, 1208-09 (10th Cir. 2000)). A survey of case law shows that “rejection of expert testimony is the exception rather than the rule.” See Fed. R. Evid.

702 advisory committee's note to 2000 amendment. DISCUSSION I. Expert Qualifications Defendant challenges Dr. Horn’s qualifications, asserting that Dr. Horn is unqualified “regarding safety of prescriptions and drug interactions” because he is not a pharmacist.2 Report [Doc. No. 37 at p. 1-2]. Rule 702 states that an expert witness may be qualified by “knowledge, skill, experience, training, or education.” Fed. R. Evid. 702. In general, “an expert is permitted

Free access — add to your briefcase to read the full text and ask questions with AI

United States v. Jarjoura, (W.D. Okla. 2025).

United States v. Jarjoura (United States v. Jarjoura) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
Kumho Tire Co. v. Carmichael
526 U.S. 137 (Supreme Court, 1999)
Taylor v. Cooper Tire & Rubber Co.
130 F.3d 1395 (Tenth Circuit, 1997)
United States v. Velarde
214 F.3d 1204 (Tenth Circuit, 2000)
Ralston v. Smith & Nephew Richards, Inc.
275 F.3d 965 (Tenth Circuit, 2001)
Sims v. Great American Life Insurance
469 F.3d 870 (Tenth Circuit, 2006)
103 Investors I, LP v. Square D Company
470 F.3d 985 (Tenth Circuit, 2006)
United States v. Nacchio
555 F.3d 1234 (Tenth Circuit, 2009)
Wilkins v. Kmart Corp.
487 F. Supp. 2d 1216 (D. Kansas, 2007)